...
opt-img

Opthea Ltd, Common Stock

OPT

NSQ

$3.3

-$0.19

(-5.44%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$555.40M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
11.27K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.54
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.79 L
$5.45 H
$3.3

About Opthea Ltd, Common Stock

Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company's lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema. It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in South Yarra, Australia. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameOPTSectorS&P500
1-Week Return-9.59%-2.82%0.15%
1-Month Return-20.02%-4.22%1.78%
3-Month Return4.76%-9.52%8.7%
6-Month Return68.8%-3.45%12.24%
1-Year Return34.69%5.62%30.9%
3-Year Return-53.72%3.8%30.19%
5-Year Return-79.83%39.68%91.72%
10-Year Return-34.46%105.02%203.2%

Financials

Jun '20Jun '21Jun '22Jun '23Jun '245YR TREND
Total Revenue59.06K91.98K125.05K161.16K124.67K[{"date":"2020-06-30","value":36.65,"profit":true},{"date":"2021-06-30","value":57.07,"profit":true},{"date":"2022-06-30","value":77.59,"profit":true},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":77.35,"profit":true}]
Cost of Revenue517.26K571.98K232.47K250.47K240.14K[{"date":"2020-06-30","value":90.43,"profit":true},{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":40.64,"profit":true},{"date":"2023-06-30","value":43.79,"profit":true},{"date":"2024-06-30","value":41.98,"profit":true}]
Gross Profit(458.20K)(480.00K)(107.42K)(89.31K)124.67K[{"date":"2020-06-30","value":-367.54,"profit":false},{"date":"2021-06-30","value":-385.03,"profit":false},{"date":"2022-06-30","value":-86.17,"profit":false},{"date":"2023-06-30","value":-71.64,"profit":false},{"date":"2024-06-30","value":100,"profit":true}]
Gross Margin(775.81%)(521.85%)(85.91%)(55.42%)100.00%[{"date":"2020-06-30","value":-775.81,"profit":false},{"date":"2021-06-30","value":-521.85,"profit":false},{"date":"2022-06-30","value":-85.91,"profit":false},{"date":"2023-06-30","value":-55.42,"profit":false},{"date":"2024-06-30","value":100,"profit":true}]
Operating Expenses17.02M53.13M133.29M223.46M191.97M[{"date":"2020-06-30","value":7.62,"profit":true},{"date":"2021-06-30","value":23.78,"profit":true},{"date":"2022-06-30","value":59.65,"profit":true},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":85.91,"profit":true}]
Operating Income59.06K(53.18M)(133.27M)(223.45M)(191.84M)[{"date":"2020-06-30","value":100,"profit":true},{"date":"2021-06-30","value":-90041.52,"profit":false},{"date":"2022-06-30","value":-225648.19,"profit":false},{"date":"2023-06-30","value":-378336.4,"profit":false},{"date":"2024-06-30","value":-324821.34,"profit":false}]
Total Non-Operating Income/Expense978.23K(13.86M)(3.17M)(80.90M)(64.68M)[{"date":"2020-06-30","value":100,"profit":true},{"date":"2021-06-30","value":-1416.59,"profit":false},{"date":"2022-06-30","value":-324.16,"profit":false},{"date":"2023-06-30","value":-8270.04,"profit":false},{"date":"2024-06-30","value":-6611.93,"profit":false}]
Pre-Tax Income(16.80M)(67.41M)(136.68M)(220.69M)(229.65M)[{"date":"2020-06-30","value":-1680115900,"profit":false},{"date":"2021-06-30","value":-6740894900,"profit":false},{"date":"2022-06-30","value":-13667659400,"profit":false},{"date":"2023-06-30","value":-22069116000,"profit":false},{"date":"2024-06-30","value":-22965430100,"profit":false}]
Income Taxes(5.72M)(6.62M)(8.69M)(8.81M)(9.41M)[{"date":"2020-06-30","value":-572037500,"profit":false},{"date":"2021-06-30","value":-662092800,"profit":false},{"date":"2022-06-30","value":-868638000,"profit":false},{"date":"2023-06-30","value":-881047900,"profit":false},{"date":"2024-06-30","value":-941219600,"profit":false}]
Income After Taxes(11.08M)(60.79M)(127.99M)(211.88M)(220.24M)[{"date":"2020-06-30","value":-1108078400,"profit":false},{"date":"2021-06-30","value":-6078802100,"profit":false},{"date":"2022-06-30","value":-12799021400,"profit":false},{"date":"2023-06-30","value":-21188068100,"profit":false},{"date":"2024-06-30","value":-22024210500,"profit":false}]
Income From Continuous Operations(16.53M)(45.34M)(92.82M)(142.52M)(220.24M)[{"date":"2020-06-30","value":-1652928100,"profit":false},{"date":"2021-06-30","value":-4534449600,"profit":false},{"date":"2022-06-30","value":-9281737100,"profit":false},{"date":"2023-06-30","value":-14252108500,"profit":false},{"date":"2024-06-30","value":-22024210500,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-06-30","value":"-","profit":true},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}]
Net Income(11.08M)(60.79M)(127.99M)(211.88M)(220.24M)[{"date":"2020-06-30","value":-1108078300,"profit":false},{"date":"2021-06-30","value":-6078802000,"profit":false},{"date":"2022-06-30","value":-12799021400,"profit":false},{"date":"2023-06-30","value":-21188068000,"profit":false},{"date":"2024-06-30","value":-22024210500,"profit":false}]
EPS (Diluted)(0.77)0.67(0.37)(2.70)(3.14)[{"date":"2020-06-30","value":-114.36,"profit":false},{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":-55.22,"profit":false},{"date":"2023-06-30","value":-403.24,"profit":false},{"date":"2024-06-30","value":-468.66,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

OPT
Cash Ratio 2.69
Current Ratio 2.94

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

OPT
ROA (LTM) -83.43%
ROE (LTM) -3383.08%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

OPT
Debt Ratio Lower is generally better. Negative is bad. 1.40
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.40

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

OPT
Trailing PE NM
Forward PE 6.73
P/S (TTM) 2050.97
P/B 4.31
Price/FCF NM
EV/R 3971.13
EV/Ebitda NM

FAQs

What is Opthea Ltd share price today?

Opthea Ltd (OPT) share price today is $3.3

Can Indians buy Opthea Ltd shares?

Yes, Indians can buy shares of Opthea Ltd (OPT) on Vested. To buy Opthea Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in OPT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Opthea Ltd be purchased?

Yes, you can purchase fractional shares of Opthea Ltd (OPT) via the Vested app. You can start investing in Opthea Ltd (OPT) with a minimum investment of $1.

How to invest in Opthea Ltd shares from India?

You can invest in shares of Opthea Ltd (OPT) via Vested in three simple steps:

  • Click on Sign Up or Invest in OPT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Opthea Ltd shares
What is Opthea Ltd 52-week high and low stock price?

The 52-week high price of Opthea Ltd (OPT) is $5.45. The 52-week low price of Opthea Ltd (OPT) is $1.79.

What is Opthea Ltd price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Opthea Ltd (OPT) is

What is Opthea Ltd price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Opthea Ltd (OPT) is 4.31

What is Opthea Ltd dividend yield?

The dividend yield of Opthea Ltd (OPT) is 0.00%

What is the Market Cap of Opthea Ltd?

The market capitalization of Opthea Ltd (OPT) is $555.40M

What is Opthea Ltd’s stock symbol?

The stock symbol (or ticker) of Opthea Ltd is OPT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top